New hope for aggressive breast cancer: drug combo vs. chemo in Head-to-Head trial
NCT ID NCT04158362
First seen Sep 30, 2025 · Last updated May 12, 2026 · Updated 33 times
Summary
This phase 3 study compares two standard first treatments for women with ER+/HER2- breast cancer that has spread to organs like the liver or lungs. One group receives chemotherapy, while the other gets hormone therapy combined with a targeted drug called abemaciclib. The goal is to see which approach better delays cancer growth and maintains quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Eugène Marquis
Rennes, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
Conditions
Explore the condition pages connected to this study.